MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. announced that its Annual Shareholders Meeting will take place virtually on June 17, 2026, starting at 9:30 a.m. ET. Shareholders can register and participate online using a control number found in their proxy materials, with registration opening at 9:15 a.m. ET. Guests will also be able to access the meeting in a listen-only mode.

MiNK Therapeutics announced that the first patient has been dosed in its randomized Phase 2 clinical trial (C-1300-02) evaluating agenT-797 for severe acute lung injury and critical illness. This milestone marks a rapid transition from trial activation to active treatment for a first-in-class immune therapy where no approved mortality-reducing therapies exist. The trial, conducted in collaboration with UNBROKEN Ukraine, is designed to assess clinically meaningful ICU outcomes, with preliminary data expected in the second half of 2026.

MiNK Therapeutics announced new clinical and translational data for its off-the-shelf iNKT cell therapy, agenT-797, presented at the American Thoracic Society International Conference 2026 and published in Clinical Immunology Communications. The data describes a sequential immunotherapy regimen with agenT-797 and N-803 in a critically ill patient with unresolving disseminated Coccidioides immitis infection and severe acute respiratory distress syndrome. Key findings included pathogen suppression, immune cell recruitment, reduced inflammation, and activation of tissue repair, supporting the company's ongoing randomized Phase 2 clinical trial for agenT-797 in severe acute lung injury and critical illness.

MiNK Therapeutics reported a net loss of $(2.74) million for Q1 2026, an improvement from $(2.77) million in Q1 2025, with basic and diluted net loss per share improving to $(0.57) from $(0.70). The company disclosed substantial doubt about its ability to continue as a going concern for the next year, despite management's belief that current cash and anticipated funding will be sufficient. During the quarter, MiNK repaid a $5.0 million related party note and raised approximately $3.0 million from equity sales.

MiNK Therapeutics reported its first quarter 2026 financial results and provided a corporate update, highlighting the initiation of a randomized Phase 2 clinical trial for agenT-797 in severe acute lung injury, with preliminary data expected in the second half of 2026. The company also announced a non-dilutive collaboration with C-Further for pediatric cancers, providing up to $1.1 million in funding. Financially, MiNK ended the quarter with $9.5 million in cash, repaid a $5.2 million convertible note, and raised $3.0 million through at-the-market sales, reporting a net loss of $2.7 million.

MiNK Therapeutics initiated a randomized Phase 2 trial for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026. The company also reported Q1 2026 financial results, including a net loss of $2.7 million and cash and cash equivalents of $9.5 million. Recent data presentations at AACR and ASGCT strengthened the biologic rationale for agenT-797, and non-dilutive collaborations expanded the platform. An upcoming presentation at the ATS conference on May 20, 2026, will feature new clinical data.

MiNK Therapeutics announced the initiation of a randomized Phase 2 clinical trial for agenT-797, its off-the-shelf allogeneic iNKT cell therapy, in patients with severe acute lung injury (ALI) and hypoxemic respiratory failure. The study, designated C-1300-02, is being conducted in Lviv, Ukraine, in partnership with First Lviv Territorial Medical Union and UNBROKEN Ukraine, with plans to expand to U.S. sites. The trial aims to evaluate clinically meaningful ICU endpoints such as survival, ventilator-free days, and reduction of secondary infections, with preliminary data anticipated in the second half of 2026.

MiNK Therapeutics announced new data at ASGCT 2026 demonstrating that its allogeneic iNKT cell therapy, agenT-797, delivers context-dependent immune reprogramming. The same product showed TH1 pro-inflammatory activation in 34 solid tumor patients and TH2 anti-inflammatory benefits in 20 ARDS patients, without genetic engineering. Clinical activity included complete metastatic remission in oncology and improved survival in ARDS, supporting advancement into a randomized Phase 2 trial.

MiNK Therapeutics announced it will report its first quarter 2026 financial results before market open on Friday, May 15, 2026. The company will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. The update will cover recent progress in its iNKT cell therapy platform, including the advancement of agenT-797, scientific presentations, and its collaboration with C-Further for pediatric cancers.

MiNK Therapeutics, Inc. filed its definitive proxy statement for its Annual Meeting of Stockholders to be held virtually on June 17, 2026. Stockholders of record as of April 23, 2026, are entitled to vote on proposals including the election of three Class II directors (Garo Armen, Barbara Ryan, and John Holcomb) and the ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026. The company's Board of Directors consists of seven members, with five identified as independent.